EXECUTIVE SUMMARY The world is currently in the midst of a global pandemic. As a global pharmaceutical company, we feel a responsibility to do our part to relieve the burden COVID-19 has placed on countries, communities and families around the world. Clinical trials have shown that monoclonal antibodies may be effective in treating COVID-19. Lilly in partnership with AbCellara has developed a monoclonal antibody called bamlanivimab. Bamlanivimab is a recombinant neutralizing human IgG1 monoclonal antibody directed against the spike protein of SARS- CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. This Antibody Playbook provides information for state, territorial and local public health programs to plan and operationalize a bamlanivimab antibody response to COVID-19. The sections of this document cover specific areas of COVID-19 antibody program planning and implementation, as well as links to resources to assist with those efforts. The sections described in this Playbook may also overlap with routine monoclonal antibody treatment and infusion program activities. This playbook represents guidance based on Lilly’s Clinical Trial experience and National Infusion Center Association (NICA) experience in monoclonal antibody treatments and should not supersede local requirements for infusion sites of care. Please defer to local guidelines. In addition, the Playbook includes information regarding planning and implementation based on varying infusion sites of care, such as: • Existing hospital or community-based infusion sites of care • Existing clinical space (e.g., primary care practices affiliated with hospital systems, urgent care locations, emergency departments, surgery centers, dialysis centers, plasma centers, respiratory clinics and other health care delivery entities approved to administer infusion therapies) We expect most infusion treatments will be administered in one of these aforementioned infusion sites of care, but other infusion sites of care may also be considered. This Playbook provides information that may or may not be applicable to certain spaces depending on existing capabilities. Lilly Bamlanivimab Antibody Playbook | 3 PP-BM-US-0024